Kyle Diamantas holds the strongest position in trader assessments for the next FDA commissioner announcement, reflecting his appointment as acting commissioner following Marty Makary’s resignation in May 2026 and his established role overseeing the agency’s Human Foods Program. Insiders highlight Diamantas’ legal background in regulatory matters and collaborative approach as factors supporting continuity during a period of leadership transition at the Department of Health and Human Services. Sara Brenner’s share aligns with her prior service as acting commissioner and recent senior counselor role to HHS Secretary Robert F. Kennedy Jr., while Brett Giroir and Stephen Hahn draw interest from their previous high-level FDA and health policy experience. Grace Graham appears in discussions due to her deputy commissioner position focused on policy and legislation. With no formal nomination confirmed as of mid-June 2026, market pricing also incorporates the possibility of delays extending past year-end, alongside the standard Senate confirmation process required for any permanent appointee.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertKyle Diamantas 36%
Sara Brenner 19.1%
Brett Giroir 14.1%
No announcement by December 31 8.4%
$12,731 Vol.
$12,731 Vol.
31. Dez. 2026
Kyle Diamantas
47%
Stephen Hahn
5%
Brett Giroir
14%
Grace Graham
7%
Sara Brenner
19%
No announcement by December 31
8%
Kyle Diamantas 36%
Sara Brenner 19.1%
Brett Giroir 14.1%
No announcement by December 31 8.4%
$12,731 Vol.
$12,731 Vol.
31. Dez. 2026
Kyle Diamantas
$2,633 Vol.
47%
Stephen Hahn
$1,516 Vol.
5%
Brett Giroir
$2,466 Vol.
14%
Grace Graham
$3,476 Vol.
7%
Sara Brenner
$2,030 Vol.
19%
No announcement by December 31
$610 Vol.
8%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas holds the strongest position in trader assessments for the next FDA commissioner announcement, reflecting his appointment as acting commissioner following Marty Makary’s resignation in May 2026 and his established role overseeing the agency’s Human Foods Program. Insiders highlight Diamantas’ legal background in regulatory matters and collaborative approach as factors supporting continuity during a period of leadership transition at the Department of Health and Human Services. Sara Brenner’s share aligns with her prior service as acting commissioner and recent senior counselor role to HHS Secretary Robert F. Kennedy Jr., while Brett Giroir and Stephen Hahn draw interest from their previous high-level FDA and health policy experience. Grace Graham appears in discussions due to her deputy commissioner position focused on policy and legislation. With no formal nomination confirmed as of mid-June 2026, market pricing also incorporates the possibility of delays extending past year-end, alongside the standard Senate confirmation process required for any permanent appointee.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Markt eröffnet: May 12, 2026, 7:59 PM ET
Volumen
$12,731Enddatum
31. Dez. 2026Markt eröffnet
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas holds the strongest position in trader assessments for the next FDA commissioner announcement, reflecting his appointment as acting commissioner following Marty Makary’s resignation in May 2026 and his established role overseeing the agency’s Human Foods Program. Insiders highlight Diamantas’ legal background in regulatory matters and collaborative approach as factors supporting continuity during a period of leadership transition at the Department of Health and Human Services. Sara Brenner’s share aligns with her prior service as acting commissioner and recent senior counselor role to HHS Secretary Robert F. Kennedy Jr., while Brett Giroir and Stephen Hahn draw interest from their previous high-level FDA and health policy experience. Grace Graham appears in discussions due to her deputy commissioner position focused on policy and legislation. With no formal nomination confirmed as of mid-June 2026, market pricing also incorporates the possibility of delays extending past year-end, alongside the standard Senate confirmation process required for any permanent appointee.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$12,731Enddatum
31. Dez. 2026Markt eröffnet
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas holds the strongest position in trader assessments for the next FDA commissioner announcement, reflecting his appointment as acting commissioner following Marty Makary’s resignation in May 2026 and his established role overseeing the agency’s Human Foods Program. Insiders highlight Diamantas’ legal background in regulatory matters and collaborative approach as factors supporting continuity during a period of leadership transition at the Department of Health and Human Services. Sara Brenner’s share aligns with her prior service as acting commissioner and recent senior counselor role to HHS Secretary Robert F. Kennedy Jr., while Brett Giroir and Stephen Hahn draw interest from their previous high-level FDA and health policy experience. Grace Graham appears in discussions due to her deputy commissioner position focused on policy and legislation. With no formal nomination confirmed as of mid-June 2026, market pricing also incorporates the possibility of delays extending past year-end, alongside the standard Senate confirmation process required for any permanent appointee.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen